N/A N=80 A Web-Based Multimedia Intervention for Head and Neck Cancer Patients
Cancer of the Head and Neck
Primary: Patient Distress — 66.16 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=471 A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 16 — -0.09; -0.06 Percentage of HbA1c — p=0.565
N/A N=86 The Inclination of the Proximal Tibiofibular Joint Surface and Medial Compartment Knee Osteoarthritis
Osteoarthritis, Knee
Primary: The Fibular Inclination Angle of the Proximal Tibiofibular Joint Surface — 26.82; 31.99 degrees
Phase 2 N=134 Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Melanoma
Primary: Non-progression Rate After Six Cycles — 13; 18; 52; 47 Participants
Phase 2 N=20 Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
Subarachnoid Hemorrhage, Aneurysmal · Delayed Cerebral Ischemia · Vasospasm, Cerebral
Primary: Participants With Adverse Events — 2; 0; 0; 0 Participants
Phase 4 N=200 Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR) at Week 12 — 116; 66 Participants
Phase 2 N=2 Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: This Trial Will Use DOXIL and Abraxane as First or Second Line Chemotherapy in Patients With a Diagnosis of Metastatic Breast Cancer (MBC).
Phase 4 N=76 Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Spine Bone Mineral Density by Dual X-ray Absorptiometry (DXA) — 7.69; 12.70 percent change in BMD
Phase 3 N=126 Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) — 232; 210 Day — p=0.47
N/A N=17 Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
Hyperhidrosis
Primary: Change in Sweating Assessed Using Gravimetry — 267.91; 57.36; 155.14 mg
Phase 2 N=10 A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Critical Limb Ischemia · Vascular Diseases · Peripheral Arterial Disease
Primary: Number of Participants With Adverse Events (AEs) Suspected to be Related to Injections of AMG0001 — 1; 1; 1; 1 Participants
Phase 2 N=40 Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
Colon Cancer · Colorectal Cancer · Colorectal Carcinoma
Primary: Phase I - Recommended Phase II Dose (RP2D) — 560 mg
Phase 4 N=225 Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
Pulmonary Arterial Hypertension
Primary: Number of Participants With Satisfactory Clinical Response at Week 24 — 45; 23; 66; 90 Participants — p=0.0007
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Phase 4 N=24 Weight Loss With Risedronate for Bone Health
Bariatric Surgery Candidate · Bone Loss · Weight Loss
Primary: Number of Enrolled Participants That Completed All 24 Week Procedures — 8; 13 Participants